异薰草素 | 491-31-6

• 分子结构分类: 有机化合物 - 苯丙烷和聚酮 - 异香豆素及其衍生物
• 中文名称: 异薰草素
• 中文别名: 1H-2-苯并吡喃-1-酮；異薰草素
• 英文名称: isocoumarin
• 英文别名: 1H-isochromen-1-one；isocumarine；isocumarin；isochromen-1-one
• CAS: 491-31-6
• 化学式: C₉H₆O₂
• mdl: MFCD08061387
• 分子量: 146.145
• InChiKey: IQZZFVDIZRWADY-UHFFFAOYSA-N

物化性质

• 熔点：
  47°C
• 沸点：
  286°C (estimate)
• 密度：
  1.1674 (rough estimate)
• LogP：
  1.994 (est)

计算性质

• 辛醇/水分配系数(LogP)：
  1.9
• 重原子数：
  11
• 可旋转键数：
  0
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  26.3
• 氢给体数：
  0
• 氢受体数：
  2

安全信息

• 储存条件：
  2-8℃

反应信息

• 作为反应物：
  描述：

  异薰草素 在 palladium on activated charcoal 、 锂硼氢 、 乙醚 、 sodium acetate 、 乙酸酐 、 溶剂黄146 作用下， 生成 异色满
  参考文献：
  名称：

  Chatterjea, Chemische Berichte, 1958, vol. 91, p. 2636

  摘要：

  DOI：
• 作为产物：
  描述：

  1-茚酮 在 双氧水 、 sodium carbonate 作用下， 以 丙酮 为溶剂， 450.0 ℃ 、13.33 Pa 条件下， 生成 异薰草素
  参考文献：
  名称：

  Total synthesis of coriandrin and 7-demethylcoriandrin via a new synthesis of isocoumarins

  摘要：

  Indenone epoxides 8, prepared from the corresponding indenones, have been shown to undergo clean thermal rearrangement to give isocoumarins 10 in high yields. This synthesis of isocoumarins, when applied to oxaindacenone 7, resulted in the total synthesis of coriandrin (1). (C) 2000 Elsevier Science Ltd. All rights reserved.

  DOI：

  10.1016/s0040-4039(00)00441-x

文献信息

• [EN] 3-PHENYL-7-HYDROXY-ISOCOUMARINS AS MACROPHAGE MIGRATION INHIBITORY FACTOR (MIF) INHIBITORS<br/>[FR] 3-PHÉNYL-7-HYDROXY-ISOCOUMARINES SERVANT D'INHIBITEURS DU FACTEUR D'INHIBITION DE LA MIGRATION DES MACROPHAGES
  申请人：PROVOST FELLOWS & SCHOLARS COLLEGE OF THE HOLY UNDIVIDED TRINITY OF QUEEN ELIZABETH NEAR DUBLIN

  公开号：WO2015144911A1

  公开（公告）日：2015-10-01

  This invention relates to 3-phenyl-7-hydroxy-isocoumarin compounds which are MIF inhibitors, compositions comprising said inhibitors and methods for treating or preventing diseases associated with MIF.

  这项发明涉及3-苯基-7-羟基异香豆素化合物，这些化合物是MIF抑制剂，包括所述抑制剂的组合物以及用于治疗或预防与MIF相关疾病的方法。
• BIS-QUATERNARY AMMONIUM SALTS AS PAIN MODULATING AGENTS
  申请人：HOLTMAN Joseph R.

  公开号：US20110166177A1

  公开（公告）日：2011-07-07

  Provided are methods for using bis-quaternary ammonium compounds to treat inflammatory pain, neuropathic pain and nociceptive pain.

  提供了使用双季铵化合物治疗炎症性疼痛、神经病理性疼痛和伤害性疼痛的方法。
• Camptothecin derivatives as chemoradiosensitizing agents
  申请人：Yang Li-Xi

  公开号：US20070093432A1

  公开（公告）日：2007-04-26

  Camptothecin-based compounds are useful for treating a neoplasm in mammalian subjects by administering such compound to the subjects in combination with radiotherapy, i.e., the treatment of tumors with radioactive substances or radiation from a source external to the subject. Camptothecin-based compounds are modified by positioning at least one electron-affinic group around the camptothecin structure to enhance their value in combination with radiotherapy. New Camptothecin-based compounds are disclosed that are useful for treating cancer by administering the novel compounds alone or in combination with radiotherapy.

  基于紫杉醇的化合物通过将该化合物与放射疗法结合在一起向哺乳动物体内施用，对治疗肿瘤具有益处，即使用放射性物质或来自主体外部源的辐射治疗肿瘤。通过在紫杉醇结构周围定位至少一个电子亲和基团来改性基于紫杉醇的化合物，以增强它们与放射疗法结合的价值。还披露了新的基于紫杉醇的化合物，可通过单独或与放射疗法结合使用这些新化合物来治疗癌症。
• JNK INHIBITOR
  申请人：Takeda Chemical Industries, Ltd.

  公开号：EP1484320A1

  公开（公告）日：2004-12-08

  A JNK inhibitor containing a compound having an isoquinolinone skeleton or a salt thereof, such as a compound represented by the formula wherein ring A and ring B are each an optionally substituted benzene ring, X is -O-, -N=, -NR3- or -CHR3-, R2 is an acyl group, an optionally esterified or thioesterified carboxyl group, an optionally substituted carbamoyl group or an optionally substituted amino group and the like, a broken line shows a single bond or a double bond, and R1 is a hydrogen atom, an optionally substituted hydrocarbon group, an optionally substituted heterocyclic group and the like, and the like.

  一种含有异喹啉酮骨架或其盐的JNK抑制剂，例如由以下公式表示的化合物： 其中环A和环B分别是可选择取代的苯环，X是-O-，-N=，-NR3-或-CHR3-，R2是酰基，可选择酯化或硫酯化的羧基，可选择取代的氨基甲酰基或可选择取代的氨基等，虚线表示单键或双键，R1是氢原子，可选择取代的碳氢基团，可选择取代的杂环基团等。
• [EN] BIARYLRHODANINE AND PYRIDYLRHODANINE COMPOUNDS AND THEIR USE<br/>[FR] COMPOSÉS DE BIARYLRHODANINE ET DE PYRIDYLRHODANINE ET LEUR UTILISATION
  申请人：AGENCY SCIENCE TECH & RES

  公开号：WO2010024783A1

  公开（公告）日：2010-03-04

  The present invention pertains generally to the field of therapeutic compounds, and more specifically to compounds related to rhodanine, which compounds are inter alia inhibitors and/or binders of antiapoptotic/pro-survival Bcl-2 proteins such as Bcl-XL and/or Mcl-1. More specifically, the present invention is concerned with Rhodanine- based Pan-Bcl-2 inhibitors and Mcl-1 -specific inhibitors as anti-cancer compounds. The present invention also pertains to pharmaceutical compositions comprising such compounds, and the use of such compounds and compositions, both in vitro and in vivo, to inhibit and/or bind Bcl-2 proteins such as Bcl-XL and/or Mcl-1, and in the treatment of diseases and conditions that are mediated by Bcl-2 proteins, that are ameliorated by the inhibition of Bcl-2 protein function (such as Bcl-XL and/or Mcl-1 ) including proliferative conditions such as cancer, optionally in combination with another agent.

  本发明一般涉及治疗化合物领域，更具体地涉及与罗丹宁相关的化合物，这些化合物是抑制剂和/或结合剂，用于抑制和/或结合抗凋亡/促存活的Bcl-2蛋白，如Bcl-XL和/或Mcl-1。更具体地，本发明涉及基于罗丹宁的Pan-Bcl-2抑制剂和Mcl-1特异性抑制剂作为抗癌化合物。本发明还涉及包括这些化合物的药物组合物，以及在体外和体内使用这些化合物和组合物来抑制和/或结合Bcl-2蛋白，如Bcl-XL和/或Mcl-1，并用于治疗由Bcl-2蛋白介导的疾病和症状，通过抑制Bcl-2蛋白功能（如Bcl-XL和/或Mcl-1）改善的疾病和症状，包括增殖性疾病如癌症，可选择地与另一药剂联合使用。

表征谱图